These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 30885978)

  • 1. An HK2 Antisense Oligonucleotide Induces Synthetic Lethality in HK1
    Xu S; Zhou T; Doh HM; Trinh KR; Catapang A; Lee JT; Braas D; Bayley NA; Yamada RE; Vasuthasawat A; Sasine JP; Timmerman JM; Larson SM; Kim Y; MacLeod AR; Morrison SL; Herschman HR
    Cancer Res; 2019 May; 79(10):2748-2760. PubMed ID: 30885978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Tumor Agnostic Therapeutic Strategy for Hexokinase 1-Null/Hexokinase 2-Positive Cancers.
    Xu S; Herschman HR
    Cancer Res; 2019 Dec; 79(23):5907-5914. PubMed ID: 31434645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A precision therapeutic strategy for hexokinase 1-null, hexokinase 2-positive cancers.
    Xu S; Catapang A; Braas D; Stiles L; Doh HM; Lee JT; Graeber TG; Damoiseaux R; Shirihai O; Herschman HR
    Cancer Metab; 2018; 6():7. PubMed ID: 29988332
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hexokinase 2 is targetable for HK1 negative, HK2 positive tumors from a wide variety of tissues of origin.
    Xu S; Catapang A; Doh HM; Bayley NA; Lee JT; Braas D; Graeber TG; Herschman HR
    J Nucl Med; 2018 Jun; 60(2):212-7. PubMed ID: 29880505
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of lentivirus-mediated shRNA inactivation of HK1, HK2, and HK3 genes in colorectal cancer and melanoma cells.
    Kudryavtseva AV; Fedorova MS; Zhavoronkov A; Moskalev AA; Zasedatelev AS; Dmitriev AA; Sadritdinova AF; Karpova IY; Nyushko KM; Kalinin DV; Volchenko NN; Melnikova NV; Klimina KM; Sidorov DV; Popov AY; Nasedkina TV; Kaprin AD; Alekseev BY; Krasnov GS; Snezhkina AV
    BMC Genet; 2016 Dec; 17(Suppl 3):156. PubMed ID: 28105937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypoxia-inducible hexokinase-2 enhances anti-apoptotic function via activating autophagy in multiple myeloma.
    Ikeda S; Abe F; Matsuda Y; Kitadate A; Takahashi N; Tagawa H
    Cancer Sci; 2020 Nov; 111(11):4088-4101. PubMed ID: 32790954
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ErbB2-upregulated HK1 and HK2 promote breast cancer cell proliferation, migration and invasion.
    Ma X; Chen J; Huang B; Fu S; Qu S; Yu R; Zhao Y
    Med Oncol; 2023 Apr; 40(5):154. PubMed ID: 37079118
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The decrease of glycolytic enzyme hexokinase 1 accelerates tumor malignancy via deregulating energy metabolism but sensitizes cancer cells to 2-deoxyglucose inhibition.
    Tseng PL; Chen CW; Hu KH; Cheng HC; Lin YH; Tsai WH; Cheng TJ; Wu WH; Yeh CW; Lin CC; Tsai HJ; Chang HC; Chuang JH; Shan YS; Chang WT
    Oncotarget; 2018 Apr; 9(27):18949-18969. PubMed ID: 29721175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. AKT1 Promotes Tumorigenesis and Metastasis by Directly Phosphorylating Hexokinases.
    Yu Y; Wang S; Wang Y; Zhang Q; Zhao L; Wang Y; Wu J; Han L; Wang J; Guo J; Xue J; Dong F; Zhang JH; Zhang L; Liu Y; Shi G; Zhang X; Li Y; Li J
    J Cell Biochem; 2024 Aug; 125(8):e30613. PubMed ID: 38860522
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting hexokinase 2 enhances response to radio-chemotherapy in glioblastoma.
    Vartanian A; Agnihotri S; Wilson MR; Burrell KE; Tonge PD; Alamsahebpour A; Jalali S; Taccone MS; Mansouri S; Golbourn B; Aldape KD; Zadeh G
    Oncotarget; 2016 Oct; 7(43):69518-69535. PubMed ID: 27588472
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FGF Trapping Inhibits Multiple Myeloma Growth through c-Myc Degradation-Induced Mitochondrial Oxidative Stress.
    Ronca R; Ghedini GC; Maccarinelli F; Sacco A; Locatelli SL; Foglio E; Taranto S; Grillo E; Matarazzo S; Castelli R; Paganini G; Desantis V; Cattane N; Cattaneo A; Mor M; Carlo-Stella C; Belotti A; Roccaro AM; Presta M; Giacomini A
    Cancer Res; 2020 Jun; 80(11):2340-2354. PubMed ID: 32094301
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Developmental profile and regulation of the glycolytic enzyme hexokinase 2 in normal brain and glioblastoma multiforme.
    Wolf A; Agnihotri S; Munoz D; Guha A
    Neurobiol Dis; 2011 Oct; 44(1):84-91. PubMed ID: 21726646
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Benserazide, a dopadecarboxylase inhibitor, suppresses tumor growth by targeting hexokinase 2.
    Li W; Zheng M; Wu S; Gao S; Yang M; Li Z; Min Q; Sun W; Chen L; Xiang G; Li H
    J Exp Clin Cancer Res; 2017 Apr; 36(1):58. PubMed ID: 28427443
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hexokinase 2 confers resistance to cisplatin in ovarian cancer cells by enhancing cisplatin-induced autophagy.
    Zhang XY; Zhang M; Cong Q; Zhang MX; Zhang MY; Lu YY; Xu CJ
    Int J Biochem Cell Biol; 2018 Feb; 95():9-16. PubMed ID: 29247711
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Loss of hexokinase 1 sensitizes ovarian cancer to high-dose metformin.
    Šimčíková D; Gardáš D; Hložková K; Hruda M; Žáček P; Rob L; Heneberg P
    Cancer Metab; 2021 Dec; 9(1):41. PubMed ID: 34895333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting hexokinase 2 inhibition promotes radiosensitization in HPV16 E7-induced cervical cancer and suppresses tumor growth.
    Liu Y; Murray-Stewart T; Casero RA; Kagiampakis I; Jin L; Zhang J; Wang H; Che Q; Tong H; Ke J; Jiang F; Wang F; Wan X
    Int J Oncol; 2017 Jun; 50(6):2011-2023. PubMed ID: 28498475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel selective hexokinase 2 inhibitor Benitrobenrazide blocks cancer cells growth by targeting glycolysis.
    Zheng M; Wu C; Yang K; Yang Y; Liu Y; Gao S; Wang Q; Li C; Chen L; Li H
    Pharmacol Res; 2021 Feb; 164():105367. PubMed ID: 33307221
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Licochalcone A suppresses hexokinase 2-mediated tumor glycolysis in gastric cancer via downregulation of the Akt signaling pathway.
    Wu J; Zhang X; Wang Y; Sun Q; Chen M; Liu S; Zou X
    Oncol Rep; 2018 Mar; 39(3):1181-1190. PubMed ID: 29286170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hexokinase 2 is required for tumor initiation and maintenance and its systemic deletion is therapeutic in mouse models of cancer.
    Patra KC; Wang Q; Bhaskar PT; Miller L; Wang Z; Wheaton W; Chandel N; Laakso M; Muller WJ; Allen EL; Jha AK; Smolen GA; Clasquin MF; Robey B; Hay N
    Cancer Cell; 2013 Aug; 24(2):213-228. PubMed ID: 23911236
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Spermatogenic cell-specific type 1 hexokinase is the predominant hexokinase in sperm.
    Nakamura N; Shibata H; O'Brien DA; Mori C; Eddy EM
    Mol Reprod Dev; 2008 Apr; 75(4):632-40. PubMed ID: 17924400
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.